Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients
Authors:
- Yan-Fu ZhengYZYan-Fu Zheng
- Xin FuXFXin Fu
- Xiao-Xu WangXWXiao-Xu Wang
- Xiao-Jing SunXSXiao-Jing Sun
- Xiao-Dan HeXHXiao-Dan He
Open Access
- 26 November 2021
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 9 (33) , 10075-10087
Abstract
Pegylated liposomal doxorubicin (PLD) uses the hydrophilic layer of liposomes to reach the sweat on the skin surface or accumulate in the sweat glands, producing toxic free radicals and oxidative damage, resulting in hand-foot syndrome (HFS). Regional cooling can induce vasoconstriction to reduce the release of drugs in the limbs and reduce the accumulation of drugs in sweat glands; thus, decreasing the incidence and severity of HFS. To study the efficacy of cooling patches to prevent HFS caused by PLD in the short-term. This is a retrospective cohort study. Female breast cancer patients (n = 101) who were treated with PLD in two breast wards at our department from February 2020 to February 2021 were enrolled in the study and were randomly divided into the cooling group (51 patients) and the control group (50 patients). Patients in the control group only received routine care, while the patients in the cooling group applied cooling patches, based on routine care, to the palm and back of the hands 15 min before chemotherapy infusion for 10 h. All patients took a corresponding dose of dexamethasone orally one day before chemotherapy, on the day of chemotherapy, and one day after chemotherapy. SPSS23.0 version was used to analyze the data in this study. The occurrence and severity of HFS was analyzed by the Mann-Whitney U test, and scores were analyzed by the Student’s t test or Wilcoxon rank-sum test. A P value < 0.05 was regarded as statistically significant. In this study, neither group of patients developed Grade 3 HFS. In the control group, the incidence of Grade 1 HFS and Grade 2 HFS was 38% and 2%, respectively. However, in the cooling group, only one person developed Grade 1 HFS (2%), and none of the patients developed Grade 2 HFS. These findings showed that cooling patches can effectively reduce the frequency and severity of HFS (P < 0.0001) in the short-term. Before the fourth chemotherapy cycle, although general self-efficacy scale scores in the cooling group were low, they were still significantly higher than those in the control group (17.22 ± 5.16 vs 19.63 ± 6.42, P = 0.041). Compared with the control group, the mean Hand-Foot Skin Reaction and Quality of Life Questionnaire score in the cooling group was significantly lower (18.08 ± 7.01 vs 14.20 ± 7.39, P = 0.008). Cooling patches can effectively reduce the frequency and severity of HFS caused by PLD in the short-term. In addition, it may help delay the decline in patients’ self-efficacy.Keywords
This publication has 27 references indexed in Scilit:
- The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for OncologyThe Oncologist, 2015
- The effectiveness of a rehabilitation programme for Chinese cancer survivors: A pilot studyInternational Journal of Nursing Practice, 2014
- Prevention of palmar–plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)The Breast, 2014
- Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal DoxorubicinHuman Cell, 2013
- Capecitabine and hand–foot syndromeExpert Opinion on Drug Safety, 2010
- Prevention strategies in palmar–plantar erythrodysesthesia onset: The role of regional coolingGynecologic Oncology, 2008
- Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective studySupportive Care in Cancer, 2007
- Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome)Annals of Oncology, 2007
- Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?Annals of Oncology, 2005
- The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma1Gynecologic Oncology, 2004